8-K: Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering IL-18 Variant Protein

Sonnet BioTherapeutics has been granted a second patent by the USPTO for its IL-18 variant protein, potentially opening licensing opportunities and strengthening its intellectual property position.

Summary

• Sonnet BioTherapeutics announced that the USPTO has issued a Notice of Allowance for a second patent related to its IL-18 variant protein.
• The patent covers the amino acid sequence of Sonnet's variant human IL-18BPR protein.
• The allowed patent claims cover variant human IL-18 (hIL-18) proteins with specific amino acid substitutions.
• Sonnet believes this patent strengthens its intellectual property and validates its approach of combining IL-18BPR with IL-12 for cancer therapy.
• The company is exploring licensing opportunities for IL-18BPR independent of its FHAB platform.
• Sonnet's lead program, SON-1010, is in Phase 1/2a study in combination with atezolizumab for the treatment of PROC.
• The company is also evaluating SON-1210 in collaboration with the Innovative Immuno-Oncology Consortium (IIOC) for solid tumors.
• Sonnet's SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Sentiment

Score: 7

Explanation: The announcement is positive due to the patent allowance, which strengthens the company's intellectual property and opens up potential licensing opportunities. However, the forward-looking statements and inherent risks associated with clinical trials and product development temper the overall sentiment.

Positives

• The new patent strengthens Sonnet's intellectual property position in the IL-18 variant protein field.
• The patent opens up potential licensing opportunities for IL-18BPR, independent of the FHAB platform.
• Management believes the patent validates their approach of combining IL-18BPR with IL-12 for cancer therapy.
• The company has two novel drug candidates, SON-1411 and SON-1400, utilizing the IL-18BPR technology.

Risks

• The announcement contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those expressed or implied in the forward-looking statements.
• The success of clinical trials and product development is not guaranteed.
• The company's cash runway is subject to change.

Future Outlook

The company anticipates the potential impact of the second patent in the IL-18 variant protein field, and continues to advance its clinical trials and product development programs.

Management Comments

• 'I believe that Sonnet has become of one of the few companies that hold proprietary rights to IL-18BPR which could be a highly valuable cytokine for cancer patients,' said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer.
• Pankaj Mohan stated that the patent covers the composition of matter of the amino acid sequence of their human IL-18BPR variant protein, bolstering their intellectual property position.
• Pankaj Mohan believes that when IL-18BPR is synergistically combined with IL-12, they will have the potential to develop an important therapeutic asset for oncology and cell-based therapy.
• John Cini, Ph.D., Sonnet Chief Scientific Officer, commented that IL-18 clinical therapies have been hampered by a lack of efficacy due to the inhibitory activity of the IL-18BP.

Industry Context

The development of targeted immunotherapies is a growing trend in the oncology field, with companies seeking to improve the efficacy and safety of treatments by targeting specific pathways and molecules involved in the immune response to cancer.

Comparison to Industry Standards

• Many companies are developing immunotherapies targeting cytokines like IL-12 and IL-15.
• Sonnet's FHAB platform is designed to improve tumor targeting and extend the half-life of linked molecules, which is a common goal in the industry.
• Companies like Roche are collaborating with smaller biotechs to evaluate novel combinations of immunotherapies, similar to Sonnet's collaboration.
• The licensing agreement with Alkem Laboratories for SON-080 is similar to other deals in the pharmaceutical industry where larger companies license assets from smaller companies for further development and commercialization.

Stakeholder Impact

• The patent allowance is positive for shareholders as it increases the value of the company's intellectual property portfolio.
• The potential for new therapies could benefit patients with cancer.
• The licensing opportunities could lead to new partnerships and revenue streams.

Next Steps

• Sonnet will continue to advance the development of its IL-18BPR-based drug candidates.
• The company will explore licensing opportunities for IL-18BPR.
• Sonnet will continue to evaluate SON-1010 in the ongoing Phase 1/2a study.
• The company plans to commence an investigator-initiated and funded Phase 1/2a study for SON-1210.

Key Dates